Shares of Dr Reddy's Laboratories will remain in focus on Wednesday after the pharma giant reported 86% year-on-year (YoY) decline in consolidated net profit to Rs 221 crore for the January-March quarter of FY26, as against Rs 1,587 crore in the year-ago period, leading to target price cuts by brokerages.
The company released its results in the post-market hours of Tuesday. Its revenue from operations, meanwhile, fell 12% YoY to Rs 7,516 crore during the quarter under review, from Rs 8,506 crore reported in the corresponding quarter of the previous financial year.
